Jasper Therapeutics, Inc. Quarterly Debt-to-equity in % from Q3 2020 to Q2 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Jasper Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q3 2020 to Q2 2025.
  • Jasper Therapeutics, Inc. Debt-to-equity for the quarter ending June 30, 2025 was 34.2 %, a 124% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2025 34.2 +18.9 +124% Jun 30, 2025
Q1 2025 21.9 +6.85 +45.7% Mar 31, 2025
Q4 2024 16.8 +2.04 +13.8% Dec 31, 2024
Q3 2024 15.6 +0.22 +1.43% Sep 30, 2024
Q2 2024 15.3 -0.83 -5.15% Jun 30, 2024
Q1 2024 15 -3.33 -18.2% Mar 31, 2024
Q4 2023 14.8 -8.02 -35.2% Dec 31, 2023
Q3 2023 15.4 -9.11 -37.2% Sep 30, 2023
Q2 2023 16.1 -11.8 -42.2% Jun 30, 2023
Q1 2023 18.3 -30.2 -62.2% Mar 31, 2023
Q4 2022 22.8 -130 -85.1% Dec 31, 2022
Q3 2022 24.5 +152 Sep 30, 2022
Q2 2022 27.9 +55.6 Jun 30, 2022
Q1 2022 48.6 +76.1 Mar 31, 2022
Q4 2021 153 +185 Dec 31, 2021
Q3 2021 -128 -85.3 -201% Sep 30, 2021
Q2 2021 -27.7 Jun 30, 2021
Q1 2021 -27.6 Mar 31, 2021
Q4 2020 -31.4 Dec 31, 2020
Q3 2020 -42.5 Sep 30, 2020
* An asterisk sign (*) next to the value indicates that the value is likely invalid.